Sign in

CIK 0001390478

  • Non-accelerated filer
  • Smaller reporting company

SELLAS Life Sciences Group, Inc.

Sign in to watch
Ticker
SLS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 646-200-5278
Business address
7 TIMES SQUARE, SUITE 2503, NEW YORK, NY, 10036
Former names
GALENA BIOPHARMA, INC., Galena Biopharma, Inc., RXI PHARMACEUTICALS CORP
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2016-06-01 Dunlap Ryan Former Chief Financial Officer Option exercise +31,250 $1.75 $55K 49,952
2016-06-01 Dunlap Ryan Former Chief Financial Officer Option exercise +65,625 $1.85 $121K 115,577
2016-06-01 Dunlap Ryan Former Chief Financial Officer Option exercise +30,000 $1.71 $51K 145,577
2016-06-01 Dunlap Ryan Former Chief Financial Officer Sale −126,875 $2.18 $277K 18,702
2016-06-01 Dunlap Ryan Former Chief Financial Officer Option exercise · Stock Option −31,250 95,625
2016-06-01 Dunlap Ryan Former Chief Financial Officer Option exercise · Stock Option −65,625 30,000
2016-06-01 Dunlap Ryan Former Chief Financial Officer Option exercise · Stock Option −30,000 0
2015-01-16 Dunlap Ryan VP, Chief Financial Officer Grant or award · Stock Option (right to buy) +125,000 125,000
2014-12-31 Dunlap Ryan VP, Chief Financial Officer Other acquisition +3,846 $1.28 $5K 11,650
2014-06-30 Dunlap Ryan VP, Chief Financial Officer Other acquisition +2,461 $2.60 $6K 7,804
2013-12-31 Dunlap Ryan Principal Accounting Officer Other acquisition +2,728 $1.88 $5K 5,343

Page 1 of 1 · 11 trades